PEGylated curcumin: A potent drug candidate

Mukesh Pandey, Sathish Rangarajan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The biomedical applications of curcumin are due to its potent antioxidant actions, inhibition of cell signaling pathways, effects on cellular enzymes, ability to alter gene transcription, apoptosis induction or a combination of these. The pharmacokinetic (PK) and pharmacodynamic (PD) studies of curcumin in rodents and in humans (Clinical Phase I) following oral dose, has shown insufficient efficacious concentration of curcumin in tissues, to exert beneficial effects. The low bioavailability of curcumin is due to rapid metabolism, aqueous insolubility and some degree of intestinal metabolism, predominantly due to glucuronidation and sulfonation. Radiolabelled studies have revealed that most of the oral dose was excreted in feces and one third of it remained structurally unchanged. Development of curcumin-based novel drug molecules devoid of low aqueous solubility and poor bioavailability is an unmet challenge. Various efforts have been made in the recent past to address this issue in depth. The most common approach attempted, has been to encapsulate curcumin in liposome or polymer-based carrier molecules. This approach has shown some degree of improvement but does not provide a practical and easy solution to the existing problem. A recent approach has been developed to incorporate various sizes of the poly(ethylene glycol) (PEG) in the curcumin back bone to address the poor aqueous solubility and bioavailability issues. The in vitro and in vivo results of PEGylated curcumin in pancreatic cancer, ovarian cancer, 3T3-L1 cell lines (fibroblast) and as Nrf2 activator in human bronchial epithelial cells have shown several-fold enhancements in efficacy compared to the free curcumin. The enhanced effects are due to higher aqueous solubility and thereby improved membrane permeability, slower clearance, prolonged systemic exposure and reduced systemic toxicity - all attributed to the presence of poly(ethylene glycol). PEGylation modulates the balance between the PK and PD properties of curcumin, and the resulting change in the PK-PD profile provides an overall improved therapeutic efficacy. This review focuses on the prospects of PEGylated curcumin as a potent drug molecule.

Original languageEnglish (US)
Title of host publicationCurcumin
Subtitle of host publicationBiosynthesis, Medicinal Uses and Health Benefits
PublisherNova Science Publishers, Inc.
Pages155-176
Number of pages22
ISBN (Print)9781619424814
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Curcumin
curcumin
drugs
Pharmaceutical Preparations
water solubility
pharmacology
Solubility
Biological Availability
pharmacokinetics
bioavailability
Ethylene Glycol
Pharmacokinetics
polyethylene glycol
mouth
3T3-L1 Cells
pancreatic neoplasms
metabolism
ovarian neoplasms
membrane permeability
dosage

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)

Cite this

Pandey, M., & Rangarajan, S. (2012). PEGylated curcumin: A potent drug candidate. In Curcumin: Biosynthesis, Medicinal Uses and Health Benefits (pp. 155-176). Nova Science Publishers, Inc..

PEGylated curcumin : A potent drug candidate. / Pandey, Mukesh; Rangarajan, Sathish.

Curcumin: Biosynthesis, Medicinal Uses and Health Benefits. Nova Science Publishers, Inc., 2012. p. 155-176.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pandey, M & Rangarajan, S 2012, PEGylated curcumin: A potent drug candidate. in Curcumin: Biosynthesis, Medicinal Uses and Health Benefits. Nova Science Publishers, Inc., pp. 155-176.
Pandey M, Rangarajan S. PEGylated curcumin: A potent drug candidate. In Curcumin: Biosynthesis, Medicinal Uses and Health Benefits. Nova Science Publishers, Inc. 2012. p. 155-176
Pandey, Mukesh ; Rangarajan, Sathish. / PEGylated curcumin : A potent drug candidate. Curcumin: Biosynthesis, Medicinal Uses and Health Benefits. Nova Science Publishers, Inc., 2012. pp. 155-176
@inbook{3d4ef0914b9d44f8a11c58b28dfbd23d,
title = "PEGylated curcumin: A potent drug candidate",
abstract = "The biomedical applications of curcumin are due to its potent antioxidant actions, inhibition of cell signaling pathways, effects on cellular enzymes, ability to alter gene transcription, apoptosis induction or a combination of these. The pharmacokinetic (PK) and pharmacodynamic (PD) studies of curcumin in rodents and in humans (Clinical Phase I) following oral dose, has shown insufficient efficacious concentration of curcumin in tissues, to exert beneficial effects. The low bioavailability of curcumin is due to rapid metabolism, aqueous insolubility and some degree of intestinal metabolism, predominantly due to glucuronidation and sulfonation. Radiolabelled studies have revealed that most of the oral dose was excreted in feces and one third of it remained structurally unchanged. Development of curcumin-based novel drug molecules devoid of low aqueous solubility and poor bioavailability is an unmet challenge. Various efforts have been made in the recent past to address this issue in depth. The most common approach attempted, has been to encapsulate curcumin in liposome or polymer-based carrier molecules. This approach has shown some degree of improvement but does not provide a practical and easy solution to the existing problem. A recent approach has been developed to incorporate various sizes of the poly(ethylene glycol) (PEG) in the curcumin back bone to address the poor aqueous solubility and bioavailability issues. The in vitro and in vivo results of PEGylated curcumin in pancreatic cancer, ovarian cancer, 3T3-L1 cell lines (fibroblast) and as Nrf2 activator in human bronchial epithelial cells have shown several-fold enhancements in efficacy compared to the free curcumin. The enhanced effects are due to higher aqueous solubility and thereby improved membrane permeability, slower clearance, prolonged systemic exposure and reduced systemic toxicity - all attributed to the presence of poly(ethylene glycol). PEGylation modulates the balance between the PK and PD properties of curcumin, and the resulting change in the PK-PD profile provides an overall improved therapeutic efficacy. This review focuses on the prospects of PEGylated curcumin as a potent drug molecule.",
author = "Mukesh Pandey and Sathish Rangarajan",
year = "2012",
month = "2",
day = "1",
language = "English (US)",
isbn = "9781619424814",
pages = "155--176",
booktitle = "Curcumin",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - PEGylated curcumin

T2 - A potent drug candidate

AU - Pandey, Mukesh

AU - Rangarajan, Sathish

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The biomedical applications of curcumin are due to its potent antioxidant actions, inhibition of cell signaling pathways, effects on cellular enzymes, ability to alter gene transcription, apoptosis induction or a combination of these. The pharmacokinetic (PK) and pharmacodynamic (PD) studies of curcumin in rodents and in humans (Clinical Phase I) following oral dose, has shown insufficient efficacious concentration of curcumin in tissues, to exert beneficial effects. The low bioavailability of curcumin is due to rapid metabolism, aqueous insolubility and some degree of intestinal metabolism, predominantly due to glucuronidation and sulfonation. Radiolabelled studies have revealed that most of the oral dose was excreted in feces and one third of it remained structurally unchanged. Development of curcumin-based novel drug molecules devoid of low aqueous solubility and poor bioavailability is an unmet challenge. Various efforts have been made in the recent past to address this issue in depth. The most common approach attempted, has been to encapsulate curcumin in liposome or polymer-based carrier molecules. This approach has shown some degree of improvement but does not provide a practical and easy solution to the existing problem. A recent approach has been developed to incorporate various sizes of the poly(ethylene glycol) (PEG) in the curcumin back bone to address the poor aqueous solubility and bioavailability issues. The in vitro and in vivo results of PEGylated curcumin in pancreatic cancer, ovarian cancer, 3T3-L1 cell lines (fibroblast) and as Nrf2 activator in human bronchial epithelial cells have shown several-fold enhancements in efficacy compared to the free curcumin. The enhanced effects are due to higher aqueous solubility and thereby improved membrane permeability, slower clearance, prolonged systemic exposure and reduced systemic toxicity - all attributed to the presence of poly(ethylene glycol). PEGylation modulates the balance between the PK and PD properties of curcumin, and the resulting change in the PK-PD profile provides an overall improved therapeutic efficacy. This review focuses on the prospects of PEGylated curcumin as a potent drug molecule.

AB - The biomedical applications of curcumin are due to its potent antioxidant actions, inhibition of cell signaling pathways, effects on cellular enzymes, ability to alter gene transcription, apoptosis induction or a combination of these. The pharmacokinetic (PK) and pharmacodynamic (PD) studies of curcumin in rodents and in humans (Clinical Phase I) following oral dose, has shown insufficient efficacious concentration of curcumin in tissues, to exert beneficial effects. The low bioavailability of curcumin is due to rapid metabolism, aqueous insolubility and some degree of intestinal metabolism, predominantly due to glucuronidation and sulfonation. Radiolabelled studies have revealed that most of the oral dose was excreted in feces and one third of it remained structurally unchanged. Development of curcumin-based novel drug molecules devoid of low aqueous solubility and poor bioavailability is an unmet challenge. Various efforts have been made in the recent past to address this issue in depth. The most common approach attempted, has been to encapsulate curcumin in liposome or polymer-based carrier molecules. This approach has shown some degree of improvement but does not provide a practical and easy solution to the existing problem. A recent approach has been developed to incorporate various sizes of the poly(ethylene glycol) (PEG) in the curcumin back bone to address the poor aqueous solubility and bioavailability issues. The in vitro and in vivo results of PEGylated curcumin in pancreatic cancer, ovarian cancer, 3T3-L1 cell lines (fibroblast) and as Nrf2 activator in human bronchial epithelial cells have shown several-fold enhancements in efficacy compared to the free curcumin. The enhanced effects are due to higher aqueous solubility and thereby improved membrane permeability, slower clearance, prolonged systemic exposure and reduced systemic toxicity - all attributed to the presence of poly(ethylene glycol). PEGylation modulates the balance between the PK and PD properties of curcumin, and the resulting change in the PK-PD profile provides an overall improved therapeutic efficacy. This review focuses on the prospects of PEGylated curcumin as a potent drug molecule.

UR - http://www.scopus.com/inward/record.url?scp=84892300279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892300279&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892300279

SN - 9781619424814

SP - 155

EP - 176

BT - Curcumin

PB - Nova Science Publishers, Inc.

ER -